← Back

Chongqing Zhifei Bio Products

Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.

Price · split & dividend adjusted
News & notes moving 300122.CS
Biotech & Genomic Medicineimpact 4

Moderna's mRNA cancer vaccine succeeds in Phase III trial, boosting related domestic industry chain stocks

The personalized mRNA cancer vaccine Intismeran, jointly developed by Moderna and Merck, has met its primary endpoint in a Phase III clinical trial, becoming the world's first individualized neoantigen therapy and mRNA cancer treatment to achieve a positive readout in a Phase III randomized controlled study. Boosted by this news, Moderna's stock price surged 176.97 percent in a single day, and China's A-share vaccine sector saw notable movement on August 20, with Kanghua Biological and Zhifei Biological hitting their daily trading limits intraday, and Everest Medicines soaring more than 70 percent at one point. Domestic companies such as Everest Medicines, Kanghua Biological, Zhifei Biological, and MGI Tech have already made arrangements in mRNA technology platforms or underlying sequencing capabilities, but therapeutic vaccine pipelines remain in early stages, with no projects yet advancing to Phase III clinical trials. Industry insiders point out that personalized cancer vaccines involve multiple technical steps including sequencing, neoantigen selection, delivery, and individualized manufacturing. Whether overseas clinical breakthroughs can truly catalyze incremental growth in the domestic industry still depends on subsequent pipeline validation.
CLS·6dRead more ▾
Biotech & Genomic Medicine2

Zhifei Biological Subsidiary's Nasal Spray Recombinant RSV Vaccine Clinical Trial Application Accepted

Zhifei Biological's wholly owned subsidiary Zhifei Lvzhu has developed a nasal spray recombinant respiratory syncytial virus vaccine using a chimpanzee adenovirus vector, and its clinical trial application has been accepted by the National Medical Products Administration. The vaccine is intended to prevent lower respiratory tract infections caused by RSV by inducing respiratory mucosal immune responses through nasal immunization, and is expected to offer a novel non-invasive prevention option for high-risk RSV populations. As of the announcement date, no respiratory syncytial virus vaccine has been approved for marketing in China. In the first quarter of 2026, Zhifei Biological achieved revenue of 2.15 billion yuan and a net loss attributable to the parent company of 388 million yuan.
财中社·16dRead more ▾
300122.CS2

Zhifei Biological Plans to Buy Back Shares for 150 Million to 300 Million Yuan

Zhifei Biological announced plans to buy back company shares for 150 million to 300 million yuan, to be used for equity incentives or employee stock ownership plans, with a buyback price not exceeding 18.22 yuan per share.
证券时报·38dRead more ▾
300122.CS

DSBJ Plans 200 Million to 300 Million Yuan Buyback; Multiple Companies Disclose Repurchase and Share Increase Plans

DSBJ announced plans to repurchase shares for 200 million to 300 million yuan, with a buyback price not exceeding 367.04 yuan per share, for employee stock ownership plans or equity incentives. Sanhua Intelligent Controls' controlling shareholder proposed repurchasing A-shares for 200 million to 400 million yuan. Three-Circle Group plans to repurchase shares for 450 million to 900 million yuan. Huayou Cobalt plans to repurchase shares for 600 million to 1 billion yuan. Broad-Ocean Motor terminated its H-share issuance and plans to repurchase shares for 120 million to 160 million yuan. Zhifei Biological plans to repurchase shares for 150 million to 300 million yuan. Puya Semiconductor's controlling shareholder proposed repurchasing shares for 30 million to 50 million yuan. Chunzhong Technology's chairman proposed repurchasing shares for 50 million to 100 million yuan to reduce registered capital. Kedali's controlling shareholder proposed repurchasing shares for 150 million to 300 million yuan. Sany Heavy Industry's chairman proposed repurchasing shares for 400 million to 800 million yuan. On the share increase side, Chuantou Energy's controlling shareholder plans to increase holdings by 200 million to 300 million yuan. China State Construction's controlling shareholder plans to increase holdings by 500 million to 1 billion yuan. Gongda Electroacoustic's controlling shareholder's concert party plans to increase holdings by 150 million to 250 million yuan. In addition, SDIC Power plans to jointly build the Yagen II Hydropower Station with CATL, with a total investment of 33.394 billion yuan. Hangdian Cable plans a private placement to raise no more than 2.88 billion yuan for optical fiber preform and other projects. Dajin Heavy Industry's subsidiary signed a shipbuilding contract worth about 2.1 billion yuan. Xingyun Technology signed a 300 million yuan computing power service contract. Yangdian Technology's wholly-owned subsidiary signed an 860 million yuan computing power service contract. Yushun Electronics' subsidiary signed a 731 million yuan computing power server lease contract. On the performance front, Raycus Laser's first-half net profit rose 117 percent year-on-year. Han's Laser's semi-annual net profit rose 163.47 percent year-on-year. Raytron Technology's first-half net profit is expected to increase by 242 percent to 270 percent. Haozhi Electromechanical's semi-annual net profit rose 267 percent year-on-year.
为自有或自筹资金·38dRead more ▾